---
title: "Gossamer Bio’s Seralutinib Future in Doubt After PROSERA Miss in PAH Raises FDA, Funding and Viability Risks"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/279737949.md"
description: "Gossamer Bio faces significant uncertainty regarding its seralutinib program after the PROSERA trial failed to meet its primary endpoint in pulmonary arterial hypertension (PAH). The FDA may require additional studies, which could delay approval and increase costs. This situation raises concerns about the company's ability to secure funding and maintain the viability of its business. Despite these challenges, the average stock price target for GOSS is $3.69, suggesting a potential upside of 750.03%."
datetime: "2026-03-19T06:00:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279737949.md)
  - [en](https://longbridge.com/en/news/279737949.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279737949.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/279737949.md) | [English](https://longbridge.com/en/news/279737949.md)


# Gossamer Bio’s Seralutinib Future in Doubt After PROSERA Miss in PAH Raises FDA, Funding and Viability Risks

Gossamer Bio (GOSS) has disclosed a new risk, in the Innovation / R&D category.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Gossamer Bio faces significant uncertainty after PROSERA’s failure to meet its primary endpoint in PAH, as the FDA may deem the existing seralutinib dataset inadequate for approval and demand additional costly and time‑consuming studies. Any delay, dead‑end development path, or inability to raise sufficient capital would materially undermine the value and viability of its seralutinib program and overall business prospects.

The average GOSS stock price target is $3.69, implying 750.03% upside potential.

To learn more about Gossamer Bio’s risk factors, click here.

### 相關股票

- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [Direxion S&P Biotech Bear 3X (LABD.US)](https://longbridge.com/zh-HK/quote/LABD.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Gossamer Bio (GOSS.US)](https://longbridge.com/zh-HK/quote/GOSS.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)

## 相關資訊與研究

- [Vertex Pharmaceuticals Says US FDA Approves Label Expansion for Alyftrek, Trikafta](https://longbridge.com/zh-HK/news/281365753.md)
- [Matinas BioPharma receives notice from NYSE](https://longbridge.com/zh-HK/news/281662764.md)
- [<![CDATA[Pfizer and BioNTech Pause Covid Vaccine Study Following Low Enrollment Totals ]]>](https://longbridge.com/zh-HK/news/281646186.md)
- [Tozorakimab shows significant benefit in two major COPD trials](https://longbridge.com/zh-HK/news/280991938.md)
- [Merck's Enlicitide Decanoate Shows Greater LDL-C Reduction Than Oral Non-Statins At 8 Weeks](https://longbridge.com/zh-HK/news/281051985.md)